APA (7th ed.) Citation

McInnes, I. B., Coates, L. C., Sewerin, P., Lavie, F., Sharaf, M., Zimmermann, M., & Efficace, M. Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: Results from the phase 3b COSMOS clinical trial. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

McInnes, Iain B., Laura C. Coates, Philipp Sewerin, Frédéric Lavie, Mohamed Sharaf, Miriam Zimmermann, and Michela Efficace. Sustained Response to Guselkumab Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: Results from the Phase 3b COSMOS Clinical Trial. BMJ Publishing Group.

MLA (9th ed.) Citation

McInnes, Iain B., et al. Sustained Response to Guselkumab Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: Results from the Phase 3b COSMOS Clinical Trial. BMJ Publishing Group.